- |||||||||| Caprelsa (vandetanib) / Sanofi
Enrollment closed: Vandetanib Risk Minimisation Effectiveness (clinicaltrials.gov) - Jul 30, 2013 P=N/A, N=20, Active, not recruiting, N=200 --> 153 Recruiting --> Active, not recruiting
- |||||||||| temozolomide / Generic mfg., capecitabine / Generic mfg.
Enrollment change, Metastases: Capecitabine and Temozolomide for Neuroendocrine Cancers (clinicaltrials.gov) - Jun 30, 2013 P2, N=38, Active, not recruiting, Not yet recruiting --> Terminated; Efficacy demonstrated on a preliminary analysis N=29 --> 38
- |||||||||| Mekinist (trametinib) / Novartis, BeiGene, pazopanib / Generic mfg.
Enrollment change, Combination therapy, Metastases: Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma (clinicaltrials.gov) - Jun 9, 2013 P1, N=111, Recruiting, Recruiting --> Active, not recruiting N=61 --> 111
- |||||||||| Enrollment closed, IO biomarker: Autoimmune Thyroid Disease Genetic Study (clinicaltrials.gov) - Apr 8, 2013
P=N/A, N=4000, Active, not recruiting, Active, not recruiting --> Completed Enrolling by invitation --> Active, not recruiting
|